A
Aviceda Therapeutics
Harnessing the natural immune system to modulate inflammation with highly selective ligands targeting specific immune cells and diseases
About Aviceda Therapeutics
Aviceda Therapeutics is a biotechnology company focused on developing innovative treatments for inflammatory diseases by leveraging the natural immune system. The company targets specific immune cells using highly selective ligands designed for maximum specificity and efficacy. Aviceda operates in the biopharmaceutical market, serving patients with life-threatening inflammatory conditions. Its business model revolves around the discovery and development of novel drugs, utilizing proprietary high-throughput screening libraries to create synthetic ligands with high specificity and affinity to Siglecs, a family of receptors on immune cells. Aviceda generates revenue through the development and commercialization of these transformative medicines. The company primarily serves the healthcare sector, including patients, healthcare providers, and research institutions.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2018
- Headquarters
- Cambridge, United States
- Employees
- 24
- Open positions
- None listed
- Dealroom signal
- 61.6/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Jan 2025 | $208M | $830M | Longitude Capital · Digitalis Ventures · Jeito Capital · Enavate Sciences | ↗ |
| LATE VCOther financing | May 2023 | $16M | $248M | Undisclosed | ↗ |
Growth signals
Latest recorded traffic for Aviceda Therapeutics is 1.7K monthly website visits, up 41.7% over the last three months. Aviceda Therapeutics's team declined 41.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Aviceda Therapeutics in the Cambridge ecosystem
The Aviceda Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later11 investors entered at this stage
Omega Funds
TCGX
Longitude Capital
Digitalis Ventures
Jeito Capital
Enavate Sciences
OrbiMed
Marshall Wace
Logos Capital
Catalio Capital Management
Aberdeen
Other known investors1 additional known investor
Queen's University Belfast
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Aviceda Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Aviceda Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









